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Abstract
Background: Familial renal glucosuria (FRG) is characterized by persistent glucosuria in the presence of normal
serum glucose concentrations, and the absence of other impairments of tubular function. Mutations in the
sodium–glucose co-transporter 2 (SGLT2) gene (SLC5A2) are causative of FRG the long-term outcome of which
is well know. In the search for potential new drug targets for SGLT2 inhibitors with which to treat the diabetes,
expressional and functional studies of SGLT2 have been the focus of attention, but reports of these are rare.
Furthermore, it is well known that the alleles in the C-terminal are very important for the expression and
function in some genes. However, little is known about the effect of mutation in SLC5A2 C- terminal.
Case presentation: Here, we identified a FRG patient with urine glucose excretion 7.56 g/day and a novel
SLC5A2 missense mutation, c.1891G > A/p.(E631K), by DNA sequencing. Expression and function of the mutant
SGLT2 (631 K) fused to green fluorescent protein (GFP) were verified by western blotting, confocal laser microscopy, and
transport activity assays in cultured HEK293 cells. Although wild-type SGLT2–GFP and 631 K mutant–GFP fusion proteins
were properly expressed in a punctate pattern in the cell membrane, and co-localized with the cell membrane marker
DiIC18(3), the expression of the mutant fusion protein was obviously decreased (24 %). Moreover, the uptake
activity of the mutant SGLT2 631 K–GFP fusion protein was significantly decreased compared with wild-type
(3629 ± 1082 vs. 7926 ± 1153, P < 0.001).
Conclusion: These results suggest that the SLC5A2 C-terminal is very important for protein expression. We
speculate that the observed reduced expression of the mutant transporter led to a decrease in transport of
the glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3- diazol-4-yl)amino)-2-deoxyglucose. The current study provides
a starting point for further investigations of the SGLT2 molecular mechanism in FRG families, and offers
functional insights into the development of anti-diabetes drugs.
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Background
Sodium–glucose co-transporter 2 (SGLT2) belongs to
the Na + −glucose cotransporter family, and is a critical
molecule in the process of glucose re-absorption from
the urine in the proximal convoluted tubule [1]. The
SGLT2 gene, SLC5A2, encodes 672 amino acids, is
7.7 kb long with 14 exons, and has been mapped to
chromosome 16p11.2 [2]. The SGLT2 protein is located
in the early proximal convoluted tubule, segment S1,
and has a Na + −to-glucose coupling ratio of 1:1 [3].
Mutations in SLC5A2 have been recently confirmed as re-
sponsible for the vast majority of familial renal glucosuria
(FRG) cases [4, 5].
In a previous study, FRG patients were shown to have
a good prognosis, so the principle behind SGLT2 inhibi-
tor therapy is to improve diabetic conditions without in-
creasing body weight or the risk of hypoglycemia [6, 7].
SGLT2 inhibitors have gradually become a research hot-
spot, but safety problems still hinder drug development
[8]. For this reason, FRG patients are ideal models to
search for pathogenic sites, and expression and
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functional studies of SLC5A2 mutations may also enable
novel SGLT2 drug targets to be identified. However,
studies about the expression or function of mutations in
FRG are rare, and the mechanism of action of mutations
in the SGLT2 C-terminus is still unclear. This study re-
ports a novel SLC5A2 mutation in a FRG proband, and
investigates its effect on SGLT2 expression and function
using an in vitro system.
Case presentation
The patient was a 39-year-old woman who was referred
to the renal division because of repeated glucosuria. She
had no polyuria, polydipsia, or weight loss. Her blood
pressure was 120/70 mmHg, and her body weight was
55 kg. Routine urinary analysis showed 2+ to 3+ glucose
with no other abnormalities. A quantitative test for urine
glucose was 7.56 g/24 h. Her medical history and clinical
examination revealed no significant findings. Fasting
plasma glucose (4.92 mmol/l), albumin (42.8 g/l),
creatinine (97 μmol/l), sodium (139.80 mmol/l), chlor-
ide (138.5 mmol/l), potassium (3.92 mmol/l), calcium
(2.10 mmol/l), phosphate (1.04 mmol/l), magnesium
(1.08 mmol/l), bicarbonate (19.4 mmol/l), uric acid
(79 μmol/l), and hemoglobin A1C (5.3 %) were all
within normal ranges. One hundred healthy Chinese
volunteers (200 chromosomes) were included as con-
trols. Informed written consent was obtained from all
participants prior to participation in the study.
Genomic DNA was extracted by salting out from per-
ipheral white blood cells. The entire coding region and
adjacent intronic segments of SLC5A2 were screened for
mutations by the direct sequencing of PCR products.
The genomic DNA reference sequences of SLC5A2
(NG_012892.1, Gene ID: 6524, MIM: 182381, GEO Pro-
files ID: 62739973 and 65974292) and protein reference
sequences of SGLT2 (NP_003032, UniProtKB - P31639)
Fig. 1 The expression and function of a novel SGLT2 C-terminal mutant. a The familial renal glucosuria patient carries a novel SLC5A2 mutation
(c.1891G > A/p.E631K). b Western blotting of wild-type and mutant SGLT2-GFP fusion proteins in 293 cells. c Expression levels of wild-type and
mutant SGLT2-GFP. d Laser scanning confocal microscopy of wild-type and mutant SGLT2-GFP in 293 cells. e Transport activity of wild-type and
mutant SGLT2-GFP in 293 cells
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were acquired from the Entrez gene and protein database,
respectively. To exclude the possibility that the identified
mutations represented common polymorphisms, control
chromosomes were tested by PCR-restriction-fragment
length polymorphism. A novel missense SLC5A2 mutation
was found in the patient (c.1891G > A/p.E631K, Fig. 1a).
The amino acid residue (631E) was found to be highly
conserved among human SGLT subtypes and across
SGLT2 homologs in multiple species. The mutation was
not detected in any of the control 200 chromosomes,
indicating that it does not represent a common
polymorphism.
Human SGLT2 cDNA from normal kidney, generated
by reverse transcription (RT)-PCR, was cloned into the
pGEM-T easy vector (Promega, Madison, WI). Wild-
type and c.1891A mutagenized SLC5A2 generated by
site-directed mutagenesis were subcloned into the
PEXL-GFP vector [9], and verified by sequencing. Hu-
man HEK293 cells (obtained from central laboratories of
Peking Union Medical College Hospital, and originally
from the American Type Culture Collection) were
seeded into 24-well plates 24 h before transfection. Plas-
mid constructs (0.5 μg) were transfected into cultured
cells at 70–80 % confluency using X-tremeGENE HP
DNA transfection reagent according to the manufac-
turer’s instructions (Roche, Mannheim, Germany). After
24 h of incubation, expression of SGLT2 wild type–GFP
and mutant–GFP fusion proteins was detected by west-
ern blotting, confocal laser microscopy, and transport
assays as we have done in previous studies [10, 11].
Western blotting analysis (Fig. 1b) demonstrated that
631 K SGLT2 expression was significantly lower than
that of wild-type SGLT2–GFP (0.24 ± 0.14 vs. 1, P =
0.002, n = 4, Fig. 1c). Confocal imaging revealed that
both the wild-type and mutant fusion proteins were
expressed in a punctate pattern in the cell membrane,
which merged well with the cell membrane marker 1,10-
dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine per-
chlorate (DiIC18(3), Fig. 1d).
The function of wild-type SGLT2–GFP and 631 K
SGLT2–GFP fusion proteins in cultured HEK293 cells
was confirmed by transport of the glucose analog 2-(N-
(7-nitrobenz-2-oxa-1,3- diazol-4-yl)amino)-2-deoxyglucose
(2-NBDG), evaluated by fluorescence intensity using flow
cytometry. 2-NBDG uptake in HEK293 cells transfected
with wild-type SGLT2–GFP was increased about 3.5-fold
compared with those transfected with GFP-only control
vector (7926 ± 1153 vs. 2314 ± 791, P < 0.001, n = 4, Fig. 1e).
The uptake activity of the mutant SGLT2 631 K-GFP fusion
protein was significantly decreased compared with wild-
type SGLT2–GFP (3629 ± 1082 vs. 7926 ± 1153, P < 0.001,
n = 4, Fig. 1e).
The Medical Ethics Committee of the Inner Mongolia
People’s Hospital and Peking University approved the
protocol. Data were compared with the t-test or analysis
of variance followed by Fisher’s least significant differ-
ence methods for multiple comparisons. Data are shown
as the mean ± SD, and significant differences were de-
clared at P < 0.05.
Kidney proximal tubules reabsorb almost 180 g glu-
cose daily, which is filtered through the glomeruli.
SGLT2 accounts for most glucose reabsorption. It is re-
sponsible for the active transport of glucose across the
brush border membrane, and is expressed almost exclu-
sively in the kidney [1]. Recent studies have reported that
SLC5A2 mutations are causative of FRG [4, 5, 10–12]. The
long-term outcome of FRG patients is excellent, so SGLT2
inhibitors have been the subject of particular attention for
the treatment of diabetes [6, 7]. Although research into
FRG may help with a breakthrough for diabetes treatment,
expression and functional studies of SLC5A2 mutations in
FRG are rare, and the role of SGLT2 C-terminal mutations
needs further clarification.
A previous study [4] suggested that overt glucosuria
requires the individual to be homozygous or compound
heterozygous for SLC5A2 mutations. Consistent with
this, our patient with a heterozygous mutation had
“mild” glucosuria (urine glucose excretion, 7.56 g/day).
However, our findings still imply that the mutation
causes a clinically relevant SGLT2 dysfunction. Our in
vitro study of 293 cells showed that the transport activity
of the mutant SGLT2 631 K-GFP fusion proteins was
significantly lower than that of wild-type. SLC5A2 muta-
tions may reduce or abolish transporter activity by
impairing protein synthesis, processing, or insertion into
the plasma membrane. Furthermore, transporter activity
may be reduced or abolished by accelerating protein re-
moval or degradation, altering functional regulation, or
impairing intrinsic activity. The mutant SGLT2 631 K–
GFP in our study had a similar punctate membrane ex-
pression pattern to wild-type, but a decreased expression
intensity. Thus, the mutation (c.1891G > A/p.E631K) is
likely to impair protein synthesis or accelerate protein
removal or degradation. Our results also suggest that the
SGLT2 C-terminal is very important for protein expres-
sion levels. We speculate that the reduced expression of
the SGLT2 mutant is responsible for the decreased
transport activity of mutant SGLT2.
Although it was not possible to perform a family study
in the present case, identification of mutations that
cause glucosuria will enable the establishment of a geno-
typic FRG diagnosis, providing important information
for families and physicians. In general, renal biopsies are
unnecessary for FRG patients, so the effect of the 631 K
mutation on SGLT2 expression in the kidney is still
unknown. We were restricted to an in vitro study of the
expression and function of SGLT2 using GFP as a fluor-
escent label because we previously found that the SGLT2
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antibody was unsuited to use in 293 cells, COS-7 cells,
and Xenopus laevis oocytes.
Conclusions
In summary, we identified a novel SLC5A2 mutation in a
Chinese FRG patient. Upon reconstruction in cultured
cells, the SGLT2 C-terminal mutant protein showed re-
duced expression intensity and glucose transport cap-
acity compared with wild-type. The mutant transport
function may be reduced because of low mutant protein
expression. Our study provides valuable information
about the SGLT2 molecular mechanism which will be
useful for anti-diabetes drug screening.
Consent
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